Based on the reduction of amyloid β plaques, US FDA has recently approved 
Aducanumab as a disease modifying treatment for Alzheimer's disease (AD). With 
high pricing and the potential risks likely with this treatment, certainty of AD 
diagnosis becomes crucial. The current pilot study evaluated plasma levels of 
neurofilament L, an axonal injury marker and amyloid β42, a major component of 
amyloid plaques for discriminating AD from non-AD dementia (NAD). Results with 
Simoa assays indicate that a combination of neurofilament L and amyloid β42 can 
be considered as a screening tool in identifying eligible subjects for AD 
treatment/ clinical trials.